Last reviewed · How we verify

Coadministered Artesunate plus Amodiaquine

Professor Anders Björkman · FDA-approved active Small molecule

Coadministered Artesunate plus Amodiaquine is a Antimalarial combination therapy Small molecule drug developed by Professor Anders Björkman. It is currently FDA-approved for Uncomplicated malaria caused by Plasmodium falciparum, Malaria caused by Plasmodium vivax, ovale, and malariae.

Artesunate and amodiaquine work synergistically to kill malaria parasites through distinct mechanisms: artesunate generates reactive oxygen species that damage parasite proteins and DNA, while amodiaquine inhibits parasite heme detoxification.

Artesunate and amodiaquine work synergistically to kill malaria parasites through distinct mechanisms: artesunate generates reactive oxygen species that damage parasite proteins and DNA, while amodiaquine inhibits parasite heme detoxification. Used for Uncomplicated malaria caused by Plasmodium falciparum, Malaria caused by Plasmodium vivax, ovale, and malariae.

At a glance

Generic nameCoadministered Artesunate plus Amodiaquine
SponsorProfessor Anders Björkman
Drug classAntimalarial combination therapy
TargetPlasmodium falciparum heme metabolism and protein synthesis
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhaseFDA-approved

Mechanism of action

Artesunate, a semi-synthetic artemisinin derivative, is activated by parasite heme to form reactive intermediates that alkylate parasite proteins and disrupt mitochondrial function. Amodiaquine, a 4-aminoquinoline, inhibits the parasite's ability to detoxify heme, leading to accumulation of toxic heme byproducts. The combination provides enhanced and rapid parasite clearance with reduced risk of resistance development compared to monotherapy.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Coadministered Artesunate plus Amodiaquine

What is Coadministered Artesunate plus Amodiaquine?

Coadministered Artesunate plus Amodiaquine is a Antimalarial combination therapy drug developed by Professor Anders Björkman, indicated for Uncomplicated malaria caused by Plasmodium falciparum, Malaria caused by Plasmodium vivax, ovale, and malariae.

How does Coadministered Artesunate plus Amodiaquine work?

Artesunate and amodiaquine work synergistically to kill malaria parasites through distinct mechanisms: artesunate generates reactive oxygen species that damage parasite proteins and DNA, while amodiaquine inhibits parasite heme detoxification.

What is Coadministered Artesunate plus Amodiaquine used for?

Coadministered Artesunate plus Amodiaquine is indicated for Uncomplicated malaria caused by Plasmodium falciparum, Malaria caused by Plasmodium vivax, ovale, and malariae.

Who makes Coadministered Artesunate plus Amodiaquine?

Coadministered Artesunate plus Amodiaquine is developed and marketed by Professor Anders Björkman (see full Professor Anders Björkman pipeline at /company/professor-anders-bj-rkman).

What drug class is Coadministered Artesunate plus Amodiaquine in?

Coadministered Artesunate plus Amodiaquine belongs to the Antimalarial combination therapy class. See all Antimalarial combination therapy drugs at /class/antimalarial-combination-therapy.

What development phase is Coadministered Artesunate plus Amodiaquine in?

Coadministered Artesunate plus Amodiaquine is FDA-approved (marketed).

What are the side effects of Coadministered Artesunate plus Amodiaquine?

Common side effects of Coadministered Artesunate plus Amodiaquine include Nausea, Vomiting, Abdominal pain, Headache, Pruritus, Diarrhea.

What does Coadministered Artesunate plus Amodiaquine target?

Coadministered Artesunate plus Amodiaquine targets Plasmodium falciparum heme metabolism and protein synthesis and is a Antimalarial combination therapy.

Related